Cellectar Biosciences
CLRB
4 hedge funds and large institutions have $514K invested in Cellectar Biosciences in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 5 closing their positions.
50% less funds holding
Funds holding: 8 → 4 (-4)
70% less capital invested
Capital invested by funds: $1.72M → $514K (-$1.21M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$15.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$77.4K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$33K |
| 3 |
BA
Bard Associates
Chicago,
Illinois
|
-$29K |
| 4 |
Goldman Sachs
New York
|
-$16K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $242K | -$77.4K | -5 | -17% |
|
|
CAM
2
Cormorant Asset Management
Boston,
Massachusetts
| $180K | – | – | – |
|
|
AIC
3
AWM Investment Company
New York
| $77K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $7K | +$15.5K | +1 | New |
|
|
WAM
5
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| $4K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $3K | – | – | – |
|
7
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $1K | – | – | – |
|
|
BA
8
Bard Associates
Chicago,
Illinois
| – | -$29K | -1 | Closed |
|
|
9
Geode Capital Management
Boston,
Massachusetts
| – | -$33K | -1 | Closed |
|
|
10
Goldman Sachs
New York
| – | -$16K | -1 | Closed |
|
|
VKH
11
Virtu KCG Holdings
New York
| – | -$13K | -1 | Closed |
|
12
Bank of America
Charlotte,
North Carolina
| – | -$1K | – | – |
|
13
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$1K | – | – |
|
CLRB Hedge Fund Activity: Q1 2016 in Review
4 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2016, worth a combined $514K — down 70% from $1.72M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CLRB and 1 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $15.5K. The largest seller was Sabby Management, cutting an estimated $77.4K.
- 4 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2016, down from 8 in Q4 2015.
- Funds reported $514K of Cellectar Biosciences stock for Q1 2016, down 70% quarter-over-quarter.
- 1 fund opened new Cellectar Biosciences positions in Q1 2016 and 5 closed out, a net change of -4 holders.
- The largest Cellectar Biosciences buyer in Q1 2016 was UBS Group, an estimated $15.5K added.
- The largest Cellectar Biosciences seller in Q1 2016 was Sabby Management, an estimated $77.4K sold.
Based on aggregated 13F filings for Q1 2016.